A tale of two countries: all‐cause mortality among people living with <scp>HIV</scp> and receiving combination antiretroviral therapy in the <scp>UK</scp> and Canada
Sophie Patterson(Simon Fraser University), Caroline Sabin(Primary Health Care), Marina B. Klein(Royal Victoria Regional Health Centre), Jane Anderson(Baylor College of Medicine), Hasina Samji(Simon Fraser University), Nimâ Machouf(Clinique Claude-Bernard), Jielin Zhu(AIDS Vancouver), Mona Loutfy(University of Toronto), Christos Tsoukas, Sophie José(NHS England), Fabiola Martin(Institut de Recerca Biomèdica Catalunya Sud), RS Hogg(Simon Fraser University), Mark Nelson(University of Tasmania), Teresa Hill, JSG Montaner(University of British Columbia), Angela Cescon, Erin Ding(AIDS Vancouver), Janet Raboud(University Health Network), SB Rourke(Ontario HIV Treatment Network), Mark Hull(AIDS Vancouver), AN Burchell(St. Michael's Hospital), Curtis Cooper(Universität Hamburg)
Cited by 3
Related Papers
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
|Hepatology|2006|4.8k
Monkeypox Virus Infection in Humans across 16 Countries — April–June 2022
|New England Journal of Medicine|2022|2.2k
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
|New England Journal of Medicine|2009|1.1k